Q3 2025 Dr. Lal PathLabs Ltd Earnings Call Transcript
Key Points
- Dr. Lal PathLabs Ltd (BOM:539524) reported a 10.7% growth in revenues for Q3 FY25, reaching INR597 crores compared to INR539 crores in the same quarter last year.
- The company maintained a strong performance trajectory with a 6.7% increase in revenue per patient, attributed to mix management initiatives.
- Dr. Lal PathLabs Ltd is expanding its reach with plans to open 15 to 20 new labs in underserved markets, enhancing its presence in Tier 3 and Tier 4 cities.
- The company's bundled test program, Swasthfit, showed robust growth of 27.2% in Q3 FY25, contributing positively to overall performance.
- The Board of Directors approved a third interim dividend of INR6 per share, bringing the total dividend for the current year to INR18 per share, reflecting strong financial health.
- Despite revenue growth, the gross margin for Q3 FY25 was slightly lower compared to the same quarter last year, indicating cost pressures.
- Employee expenses have been growing in mid-teens, higher than revenue growth, due to investments in new infrastructure and hiring, which may impact profitability.
- Suburban Diagnostics, a part of Dr. Lal PathLabs Ltd, showed softer revenue growth of 9.2% in Q3 FY25, lagging behind the overall company growth.
- The effective tax rate remains elevated at around 29% on a consolidated basis due to depreciation on intangibles, affecting net profitability.
- The company faces challenges in expanding patient volume growth, which stood at 4.4% YTD FY25, below historical pre-COVID levels.
Ladies and gentlemen, good day, and welcome to Dr. Lal PathLabs' Q3 FY25 earnings conference call for investors and analysts. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Nishid Solanki of CDR India. Thank you, and over to you.
Thank you. Good afternoon, everyone, and welcome to Dr. Lal PathLabs' Q3 FY25 earnings conference call. Today, we are joined by senior members of the management team, including (inaudible) Arvind Lal, Executive Chairman; Dr. Om Prakash Manchanda, Managing Director; Mr. Shankha Banerjee, CEO; and Mr. Ved Prakash Goel, Group's CFO and CEO International business.
I would like to share our standard disclaimer. Some of the statements made on today's conference call could be forward-looking in nature, and the actual results could vary from these forward-looking statements. A detailed statement in this regard is available in the results presentation, which has been circulated to you and also available on stock
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
